title: De novo malignancy following liver transplantation: a single-center study.
authors.affiliation: Baylor University Medical Center, Dallas, Texas.
authors.forename: M
authors.initials: M
authors.lastname: Levy
authors.forename: L
authors.initials: L
authors.lastname: Backman
authors.forename: B
authors.initials: B
authors.lastname: Husberg
authors.forename: R
authors.initials: R
authors.lastname: Goldstein
authors.forename: R
authors.initials: R
authors.lastname: McMillan
authors.forename: J
authors.initials: J
authors.lastname: Gibbs
authors.forename: T A
authors.initials: TA
authors.lastname: Gonwa
authors.forename: M
authors.initials: M
authors.lastname: Holman
authors.forename: G
authors.initials: G
authors.lastname: Klintmalm
mesh_terms: D000328:Adult; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D015994:Incidence; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D008223:Lymphoma / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology
chemical_list: D016853:Muromonab-CD3